Is Now a Good Time to Sell a Dermatology Practice Business?

Yes. 2026 is a strong window to sell a dermatology practice. Multiples are holding at 8.0x-14.0x EBITDA for platform-quality practices and 6.0x-9.0x for tuck-ins, supported by active competition from Schweiger Dermatology, US Dermatology Partners, Forefront Dermatology, Advanced Dermatology and Cosmetic Surgery, Pinnacle Dermatology, Anne Arundel Dermatology, and QualDerm Partners. The combination of broad buyer competition, strong cash-pay and commercial revenue mix, and a continued demographic tailwind keeps dermatology near the top of the physician services valuation table.

2026 Dermatology Multiple Snapshot

  • Platform multiple range: 8.0x-14.0x EBITDA
  • Tuck-in multiple range: 6.0x-9.0x EBITDA
  • Active platform buyers: 12+ in 2026
  • Typical timeline: 6-10 months go-to-market to close

Why is now still a strong time to sell a dermatology practice?

Three forces are aligned. First, the buyer pool is broader than it has ever been — at least 12 active platform consolidators are pursuing dermatology M&A in 2026, and the second-generation acquirers (platforms that already built initial scale and are now bolting on regional add-ons) compete aggressively for the right targets. Second, multiples have held in the 8.0x-14.0x range despite higher interest rates, because dermatology revenue is largely cash and commercial pay with limited Medicare exposure compared to many other physician specialties. Third, the demographic tailwind is unchanged — aging boomer skin cancer demand is still rising, and aesthetic spending by Gen X and millennials remains at all-time highs.

The full buyer landscape and the underwriting framework each platform uses is detailed in my dermatology practice valuation hub.

Are smaller dermatology practices still attractive to buyers?

Yes, though the buyer pool shifts. Single-physician practices below $750K EBITDA see less interest from the largest national platforms, which prefer multi-physician add-ons that offer more revenue per integration cost. But regional consolidators backed by lower-middle-market PE — including QualDerm Partners, Pinnacle Dermatology, and several state-focused platforms — actively pursue $400K-$1M EBITDA tuck-ins at 6.0x-9.0x EBITDA. The structural fundamentals matter as much as size: a single-physician practice with a strong cosmetic mix, owned real estate, and a physician willing to commit to a 3-5 year employment tail will trade at a meaningful premium to one without those features.

For owners weighing parallel paths in physician services, the optometry practice valuation guide walks through a similar buyer landscape with different vertical-specific dynamics.

John's Take. Dermatology has been one of the most consistently bid-up sectors I work in for the last several years, and 2026 is no exception. I had a three-physician practice with $1.8M EBITDA in market last fall — five competitive LOIs, winning bid at 11.4x. The buyers were not chasing growth; they were chasing physician retention, Mohs capability, and clean compliance. The owners who hesitate waiting for a better window often miss the actual one.

Find Out What Your Dermatology Practice Is Worth

The dermatology buyer pool is at its broadest right now, but valuations reward preparation. Use the free valuation calculator for an initial range, then schedule a confidential consultation to walk through buyer fit and timing.

Schedule a Confidential Consultation

Frequently Asked Questions

Why is now still a strong time to sell a dermatology practice?
Three reasons. First, the buyer pool is broader than it has ever been — at least 12 active platform consolidators are pursuing dermatology M&A in 2026, and the second-generation acquirers (platforms that already bought their first round of practices and are now scaling regional rollups) are competing aggressively for the right targets. Second, multiples have stayed in the 8.0x-14.0x range despite higher interest rates, because dermatology revenue is largely cash and commercial pay, with limited Medicare exposure compared to many other physician specialties. Third, the demographic tailwind is unchanged — aging boomer skin cancer demand is still rising, and aesthetic spending by Gen X and millennials is at all-time highs. The combination keeps demand for quality practices at premium multiples, even as some other healthcare specialties have softened.
Are smaller dermatology practices still attractive to buyers?
Yes, though the buyer pool shifts. Single-physician practices below $750K EBITDA see less interest from the largest national platforms, which prefer multi-physician add-ons that offer more revenue per integration cost. But there is real competition from regional dermatology consolidators backed by lower-middle-market PE — including QualDerm Partners, Pinnacle Dermatology, and several state-focused platforms — actively pursuing $400K-$1M EBITDA tuck-ins at 6.0x-9.0x EBITDA. The structural fundamentals matter as much as size: a single-physician practice with strong cosmetic mix, owned real estate, and a physician willing to commit to a 3-5 year employment tail will trade at a meaningful premium to one without those features. Independent search funds and physician-buyer transactions also remain a viable path for smaller practices.